[1] YESUDHAS D, SRIVASTAVA A, GROMIHA M M. COVID-19 outbreak: history, mechanism, transmission, structural studies and therapeutics. Infection. 2021;49(2):199-213.
[2] DA COSTA VG, MORELI ML, SAIVISH MV. The emergence of SARS, MERS and novel SARS-2 coronaviruses in the 21st century. Arch Virol. 2020;165(7): 1517-1526.
[3] NABEL KG, CLARK SA, SHANKAR S, et al. Structural basis for continued antibody evasion by the SARS-CoV-2 receptor binding domain. Science. 2022;375(6578):eabl6251.
[4] VITIELLO A, FERRARA F, AUTI AM, et al. Advances in the Omicron variant development. J Intern Med. 2022 Mar 15. doi: 10.1111/joim.13478. Online ahead of print.
[5] ARAF Y, AKTER F, TANG YD, et al. Omicron variant of SARS-CoV-2: Genomics, transmissibility, and responses to current COVID-19 vaccines. J Med Virol. 2022;94(5):1825-1832.
[6] NGAI HW, KIM DH, HAMMAD M, et al. Stem Cell-based therapies for COVID-19-related acute respiratory distress syndrome. J Cell Mol Med. 2022;26(9):2483-2504.
[7] YAN YY, ZHOU WM, WANG YQ, et al. The Potential Role of Extracellular Vesicles in COVID-19 Treatment: Opportunity and Challenge. Front Mol Biosci. 2021;8:699929.
[8] XU X, HAN M, LI T, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci U S A. 2020;117(20):10970-10975.
[9] MEHTA P, MCAULEY DF, BROWN M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033-1034.
[10] MAZINI L, ROCHETTE L, AMINE M, et al. Regenerative Capacity of Adipose Derived Stem Cells (ADSCs), Comparison with Mesenchymal Stem Cells (MSCs). Int J Mol Sci. 2019;20(10):2523.
[11] MAZINI L, ROCHETTE L, ADMOU B, et al. Hopes and Limits of Adipose-Derived Stem Cells (ADSCs) and Mesenchymal Stem Cells (MSCs) in Wound Healing. Int J Mol Sci. 2020;21(4):1306.
[12] LAFFEY JG, MATTHAY MA. Fifty Years of Research in ARDS. Cell-based Therapy for Acute Respiratory Distress Syndrome. Biology and Potential Therapeutic Value. Am J Respir Crit Care Med. 2017;196(3):266-273.
[13] MATTHAY MA, CALFEE CS, ZHUO H, et al. Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial. Lancet Respir Med. 2019;7(2):154-162.
[14] DAULETOVA M, HAFSAN H, MAHHENGAM N, et al. Mesenchymal stem cell alongside exosomes as a novel cell-based therapy for COVID-19: A review study. Clin Immunol. 2021;226:108712.
[15] O’LEARY VB, DOLLY OJ, HÖSCHL C, et al. Unpacking Pandora From Its Box: Deciphering the Molecular Basis of the SARS-CoV-2 Coronavirus. Int J Mol Sci. 2020;22(1):386.
[16] WRAPP D, WANG N, CORBETT KS, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020;367(6483):1260-1263.
[17] SCHELLER N, HEROLD S, KELLNER R, et al. Proviral MicroRNAs Detected in Extracellular Vesicles From Bronchoalveolar Lavage Fluid of Patients With Influenza Virus-Induced Acute Respiratory Distress Syndrome. J Infect Dis. 2019;219(4):540-543.
[18] HAMMING I, TIMENS W, BULTHUIS ML, et al. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. 2004;203(2):631-637.
[19] YIN W, XU Y, XU P, et al. Structures of the Omicron spike trimer with ACE2 and an anti-Omicron antibody. Science. 2022;375(6584):1048-1053.
[20] ZHAO Y, ZHAO Z, WANG Y, et al. Single-Cell RNA Expression Profiling of ACE2, the Receptor of SARS-CoV-2. Am J Respir Crit Care Med. 2020;202(5):756-759.
[21] GUZIK TJ, MOHIDDIN SA, DIMARCO A, et al. COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options. Cardiovasc Res. 2020;116(10):1666-1687.
[22] BOURGONJE AR, ABDULLE AE, TIMENS W, et al. Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19). J Pathol. 2020;251(3):228-248.
[23] YANG L, LIU S, LIU J, et al. COVID-19: immunopathogenesis and Immunotherapeutics. Signal Transduct Target Ther. 2020;5(1):128.
[24] PEDERSEN SF, HO YC. SARS-CoV-2: a storm is raging. J Clin Invest. 2020; 130(5):2202-2205.
[25] ENGLAND JT, ABDULLA A, BIGGS CM, et al. Weathering the COVID-19 storm: Lessons from hematologic cytokine syndromes. Blood Rev. 2021;45:100707.
[26] GAO YM, XU G, WANG B, et al. Cytokine storm syndrome in coronavirus disease 2019: A narrative review. J Intern Med. 2021;289(2):147-161.
[27] CAPLAN AI. Mesenchymal stem cells. J Orthop Res. 1991;9(5):641-650.
[28] BABAJANI A, SOLTANI P, JAMSHIDI E, et al. Recent Advances on Drug-Loaded Mesenchymal Stem Cells With Anti-neoplastic Agents for Targeted Treatment of Cancer. Front Bioeng Biotechnol. 2020;8:748.
[29] YOUSEFI DEHBIDI M, GOODARZI N, AZHDARI MH, et al. Mesenchymal stem cells and their derived exosomes to combat Covid-19. Rev Med Virol. 2022;32(2):e2281.
[30] GOLCHIN A, FARAHANY TZ, KHOJASTEH A, et al. The Clinical Trials of Mesenchymal Stem Cell Therapy in Skin Diseases: An Update and Concise Review. Curr Stem Cell Res Ther. 2019;14(1):22-33.
[31] WHELAN DS, CAPLICE NM, CLOVER AJP. Mesenchymal stromal cell derived CCL2 is required for accelerated wound healing. Sci Rep. 2020;10(1):2642.
[32] GAZDIC M, VOLAREVIC V, ARSENIJEVIC N, et al. Mesenchymal stem cells: a friend or foe in immune-mediated diseases. Stem Cell Rev Rep. 2015; 11(2):280-287.
[33] RAHMATI S, SHOJAEI F, SHOJAEIAN A, et al. An overview of current knowledge in biological functions and potential theragnostic applications of exosomes. Chem Phys Lipids. 2020;226:104836.
[34] DOYLE LM, WANG MZ. Overview of Extracellular Vesicles, Their Origin, Composition, Purpose, and Methods for Exosome Isolation and Analysis. Cells. 2019;8(7):727.
[35] YIN K, WANG S, ZHAO RC. Exosomes from mesenchymal stem/stromal cells: a new therapeutic paradigm. Biomark Res. 2019;7:8.
[36] PASHOUTAN SARVAR D, SHAMSASENJAN K, AKBARZADEHLALEH P. Mesenchymal Stem Cell-Derived Exosomes: New Opportunity in Cell-Free Therapy. Adv Pharm Bull. 2016;6(3):293-299.
[37] GAO F, CHIU SM, MOTAN DA, et al. Mesenchymal stem cells and immunomodulation: current status and future prospects. Cell Death Dis. 2016;7(1):e2062.
[38] EL ANDALOUSSI S, MÄGER I, BREAKEFIELD XO, et al. Extracellular vesicles: biology and emerging therapeutic opportunities. Nat Rev Drug Discov. 2013; 12(5):347-357.
[39] JAMSHIDI E, BABAJANI A, SOLTANI P, et al. Proposed Mechanisms of Targeting COVID-19 by Delivering Mesenchymal Stem Cells and Their Exosomes to Damaged Organs. Stem Cell Rev Rep. 2021;17(1):176-192.
[40] HE X, DONG Z, CAO Y, et al. MSC-Derived Exosome Promotes M2 Polarization and Enhances Cutaneous Wound Healing. Stem Cells Int. 2019; 2019:7132708.
[41] KHEIRKHAH AH, SHAHCHERAGHI SH, LOTFI M, et al. Mesenchymal Stem Cell Derived-Exosomes as Effective Factors in Reducing Cytokine Storm Symptoms of COVID-19. Protein Pept Lett. 2021;28(8):945-952.
[42] LIU S, PENG D, QIU H, et al. Mesenchymal stem cells as a potential therapy for COVID-19. Stem Cell Res Ther. 2020;11(1):169.
[43] TEUWEN LA, GELDHOF V, PASUT A, et al. COVID-19: the vasculature unleashed. Nat Rev Immunol. 2020;20(7):389-391.
[44] BARI E, FERRAROTTI I, DI SILVESTRE D, et al. Adipose Mesenchymal Extracellular Vesicles as Alpha-1-Antitrypsin Physiological Delivery Systems for Lung Regeneration. Cells. 2019;8(9):965.
[45] YANG Y, CHEN QH, LIU AR, et al. Synergism of MSC-secreted HGF and VEGF in stabilising endothelial barrier function upon lipopolysaccharide stimulation via the Rac1 pathway. Stem Cell Res Ther. 2015;6:250.
[46] LI X, GENG M, PENG Y, et al. Molecular immune pathogenesis and diagnosis of COVID-19. J Pharm Anal. 2020;10(2):102-108.
[47] DEVANEY J, HORIE S, MASTERSON C, et al. Human mesenchymal stromal cells decrease the severity of acute lung injury induced by E. coli in the rat. Thorax. 2015;70(7):625-635.
[48] LEE JW, FANG X, GUPTA N, et al. Allogeneic human mesenchymal stem cells for treatment of E. coli endotoxin-induced acute lung injury in the ex vivo perfused human lung. Proc Natl Acad Sci U S A. 2009;106(38): 16357-16362.
[49] GARCIA-REVILLA J, DEIERBORG T, VENERO JL, et al. Hyperinflammation and Fibrosis in Severe COVID-19 Patients: Galectin-3, a Target Molecule to Consider. Front Immunol. 2020;11:2069.
[50] CAI Q, YIN F, HAO L, et al. Research Progress of Mesenchymal Stem Cell Therapy for Severe COVID-19. Stem Cells Dev. 2021;30(9):459-472.
[51] HAO Q, GUDAPATI V, MONSEL A, et al. Mesenchymal Stem Cell-Derived Extracellular Vesicles Decrease Lung Injury in Mice. J Immunol. 2019; 203(7):1961-1972.
[52] KIM J, YANG YL, JEONG Y, et al. Middle East Respiratory Syndrome-Coronavirus Infection into Established hDPP4-Transgenic Mice Accelerates Lung Damage Via Activation of the Pro-Inflammatory Response and Pulmonary Fibrosis. J Microbiol Biotechnol. 2020;30(3):427-438.
[53] ZENG SL, WANG LH, LI P, et al. Mesenchymal stem cells abrogate experimental asthma by altering dendritic cell function. Mol Med Rep. 2015;12(2):2511-2520.
[54] BAO L, DENG W, HUANG B, et al. The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice. Nature. 2020;583(7818):830-833.
[55] POPOWSKI KD, DINH PC, GEORGE A, et al. Exosome therapeutics for COVID-19 and respiratory viruses. View (Beijing). 2021:20200186.
[56] MONSEL A, ZHU YG, GENNAI S, et al. Therapeutic Effects of Human Mesenchymal Stem Cell-derived Microvesicles in Severe Pneumonia in Mice. Am J Respir Crit Care Med. 2015;192(3):324-336.
[57] LENG Z, ZHU R, HOU W, et al. Transplantation of ACE2- Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia. Aging Dis. 2020;11(2):216-228.
[58] LIANG B, CHEN J, LI T, et al. Clinical remission of a critically ill COVID-19 patient treated by human umbilical cord mesenchymal stem cells: A case report. Medicine (Baltimore). 2020;99(31):e21429.
[59] SENGUPTA V, SENGUPTA S, LAZO A, et al. Exosomes Derived from Bone Marrow Mesenchymal Stem Cells as Treatment for Severe COVID-19. Stem Cells Dev. 2020;29(12):747-754.
[60] GUPTA A, KASHTE S, GUPTA M, et al. Mesenchymal stem cells and exosome therapy for COVID-19: current status and future perspective. Hum Cell. 2020;33(4):907-918.
[61] GOLCHIN A, SEYEDJAFARI E, ARDESHIRYLAJIMI A. Mesenchymal Stem Cell Therapy for COVID-19: Present or Future. Stem Cell Rev Rep. 2020;16(3): 427-433.
[62] SHU L, NIU C, LI R, et al. Treatment of severe COVID-19 with human umbilical cord mesenchymal stem cells. Stem Cell Res Ther. 2020;11(1):361.
[63] RAGHAV A, KHAN ZA, UPADHAYAY VK, et al. Mesenchymal Stem Cell-Derived Exosomes Exhibit Promising Potential for Treating SARS-CoV-2-Infected Patients. Cells. 2021;10(3):587.
[64] WEN S, DOONER M, PAPA E, et al. Biodistribution of Mesenchymal Stem Cell-Derived Extracellular Vesicles in a Radiation Injury Bone Marrow Murine Model. Int J Mol Sci. 2019;20(21):5468.
|